Cargando…

Evaluation of immune response following one dose of an AS03(A)-adjuvanted H1N1 2009 pandemic influenza vaccine in Japanese adults 65 years of age or older

Objective: This study assessed the immunogenicity, long-term persistence of immune response and safety of a single dose of an A/California/07/2009 H1N1 pandemic influenza vaccine adjuvanted with AS03 (α-tocopherol and squalene based oil-in-water emulsion Adjuvant System) in subjects ≥ 65 y of age (N...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ikematsu, Hideyuki, Tenjinbaru, Kazuyoshi, Li, Ping, Madan, Anuradha, Vaughn, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2012
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551884/ https://www.ncbi.nlm.nih.gov/pubmed/22854661 http://dx.doi.org/10.4161/hv.21081

Ejemplares similares

Characterization and long-term persistence of immune response following two doses of an AS03A-adjuvanted H1N1 influenza vaccine in healthy Japanese adults
por: Ikematsu, Hideyuki, et al.
Publicado: (2012)

A phase II, open-label, multicentre study to evaluate the immunogenicity and safety of an adjuvanted prepandemic (H5N1) influenza vaccine in healthy Japanese adults
por: Nagai, Hideaki, et al.
Publicado: (2010)

Rapid Immunization Against H5N1: A Randomized Trial Evaluating Homologous and Cross-Reactive Immune Responses to AS03(A)-Adjuvanted Vaccination in Adults
por: Lasko, Benjamin, et al.
Publicado: (2011)

Extended antigen sparing potential of AS03-adjuvanted pandemic H1N1 vaccines in children, and immunological equivalence of two formulations of AS03-adjuvanted H1N1 vaccines: results from two randomised trials
por: Launay, Odile, et al.
Publicado: (2013)

Risk of Narcolepsy Associated with Inactivated Adjuvanted (AS03) A/H1N1 (2009) Pandemic Influenza Vaccine in Quebec
por: Montplaisir, Jacques, et al.
Publicado: (2014)

Safety of AS03-adjuvanted split-virion H1N1 (2009) pandemic influenza vaccine: a prospective cohort study
por: Nazareth, Irwin, et al.
Publicado: (2013)

Clinical features of narcolepsy in children vaccinated with AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine in England
por: Winstone, Anne Marie, et al.
Publicado: (2014)

IF-03 Clinical Effectiveness of Oseltamivir or Zanamivir for Influenza A/H1N1 Virus with or without H274Y Mutation
por: Kawai, Naoki, et al.
Publicado: (2009)

Effectiveness of the AS03-Adjuvanted Vaccine against Pandemic Influenza Virus A/(H1N1) 2009 – A Comparison of Two Methods; Germany, 2009/10
por: Uphoff, Helmut, et al.
Publicado: (2011)

Multi-Centre Observational Study of Transplacental Transmission of Influenza Antibodies following Vaccination with AS03(A)-Adjuvanted H1N1 2009 Vaccine
por: Puleston, Richard, et al.
Publicado: (2013)

Short and Long-Term Safety of the 2009 AS03-Adjuvanted Pandemic Vaccine
por: De Serres, Gaston, et al.
Publicado: (2012)

Immunogenicity and Safety of an AS03-Adjuvanted H7N9 Pandemic Influenza Vaccine in a Randomized Trial in Healthy Adults
por: Madan, Anuradha, et al.
Publicado: (2016)

Non‐neutralizing antibody responses following A(H1N1)pdm09 influenza vaccination with or without AS03 adjuvant system
por: Friel, Damien, et al.
Publicado: (2020)

AS03- and MF59-Adjuvanted Influenza Vaccines in Children
por: Wilkins, Amanda L., et al.
Publicado: (2017)

Adjuvanted (AS03) A/H1N1 2009 Pandemic Influenza Vaccines and Solid Organ Transplant Rejection: Systematic Signal Evaluation and Lessons Learnt
por: Dos Santos, Gaël, et al.
Publicado: (2017)

Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: An observer-blind, randomized trial()
por: Yang, William H., et al.
Publicado: (2013)

Comparing the Immunogenicity of AS03-Adjuvanted 2009 Pandemic H1N1 Vaccine with Clinical Protection in Priority Risk Groups in England
por: Yung, Chee-Fu, et al.
Publicado: (2013)

Heterologous Prime-Boost Vaccination Using an AS03(B)-Adjuvanted Influenza A(H5N1) Vaccine in Infants and Children <3 Years of Age
por: Nolan, Terry, et al.
Publicado: (2014)

Flexibility of interval between vaccinations with AS03(A)-adjuvanted influenza A (H1N1) 2009 vaccine in adults aged 18–60 and >60 years: a randomized trial
por: Duval, Xavier, et al.
Publicado: (2012)

Effect of the adjuvanted (AS03) A/H1N1 2009 pandemic influenza vaccine on the risk of rejection in solid organ transplant recipients in England: a self-controlled case series
por: Cohet, Catherine, et al.
Publicado: (2016)

Investigating the effect of AS03 adjuvant on the plasma cell repertoire following pH1N1 influenza vaccination
por: Galson, J. D., et al.
Publicado: (2016)

Comparative Postmarket Safety Profile of Adjuvanted and High-Dose Influenza Vaccines in Individuals 65 Years or Older
por: Pillsbury, Alexis J., et al.
Publicado: (2020)

Influenza symptoms and their impact on elderly adults: randomised trial of AS03-adjuvanted or non-adjuvanted inactivated trivalent seasonal influenza vaccines
por: van Essen, Gerrit A, et al.
Publicado: (2014)

Relative Efficacy of AS03-Adjuvanted Pandemic Influenza A(H1N1) Vaccine in Children: Results of a Controlled, Randomized Efficacy Trial
por: Nolan, Terry, et al.
Publicado: (2014)

Risk of presentation to hospital with epileptic seizures after vaccination with monovalent AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine (Pandemrix): self controlled case series study
por: Arnheim-Dahlström, Lisen, et al.
Publicado: (2012)

Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009
por: Skowronski, Danuta M, et al.
Publicado: (2011)

Safety of AS03-adjuvanted inactivated split virion A(H1N1)pdm09 and H5N1 influenza virus vaccines administered to adults: Pooled analysis of 28 clinical trials
por: Vaughn, David W, et al.
Publicado: (2014)

AS03-Adjuvanted, Very-Low-Dose Influenza Vaccines Induce Distinctive Immune Responses Compared to Unadjuvanted High-Dose Vaccines in BALB/c Mice
por: Yam, Karen K., et al.
Publicado: (2015)

Immunogenicity and Safety of AS03-adjuvanted H5N1 Influenza Vaccine in Children 6–35 Months of Age: Results From a Phase 2, Randomized, Observer-blind, Multicenter, Dose-ranging Study
por: Kim, Joon Hyung, et al.
Publicado: (2021)

Long-Term Persistence of Cell-Mediated and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults during Two Randomized Controlled Trials
por: van der Most, Robbert G., et al.
Publicado: (2017)

Tropism of Pandemic 2009 H1N1 Influenza a Virus
por: Ramadhany, Ririn, et al.
Publicado: (2012)

Narcolepsy and adjuvanted pandemic influenza A (H1N1) 2009 vaccines – Multi-country assessment
por: Weibel, Daniel, et al.
Publicado: (2018)

A randomized, controlled non-inferiority trial comparing A(H1N1)pmd09 vaccine antigen, with and without AS03 adjuvant system, co-administered or sequentially administered with an inactivated trivalent seasonal influenza vaccine
por: Langley, Joanne M, et al.
Publicado: (2012)

Antigenic Differences between AS03 Adjuvanted Influenza A (H1N1) Pandemic Vaccines: Implications for Pandemrix-Associated Narcolepsy Risk
por: Vaarala, Outi, et al.
Publicado: (2014)

Pandemic Influenza (H1N1) 2009 Pneumonia: CURB-65 Score for Predicting Severity and Nasopharyngeal Sampling for Diagnosis Are Unreliable
por: Mulrennan, Siobhain, et al.
Publicado: (2010)

AS03(B)-Adjuvanted H5N1 Influenza Vaccine in Children 6 Months Through 17 Years of Age: A Phase 2/3 Randomized, Placebo-Controlled, Observer-Blinded Trial
por: Kosalaraksa, Pope, et al.
Publicado: (2015)

Safety and immunogenicity of 2010–2011 A/H1N1pdm09-containing trivalent inactivated influenza vaccine in adults previously given AS03-adjuvanted H1N1 2009 pandemic vaccine: Results of a randomized trial
por: Scheifele, David W., et al.
Publicado: (2013)

HIV virological suppression influences response to the AS03-adjuvanted monovalent pandemic influenza A H1N1 vaccine in HIV-infected children
por: Leahy, Timothy R, et al.
Publicado: (2014)

Safety, Reactogenicity, and Immunogenicity of Inactivated Monovalent Influenza A(H5N1) Virus Vaccine Administered With or Without AS03 Adjuvant
por: Chen, Wilbur H., et al.
Publicado: (2014)

Cost-Effectiveness of the Adjuvant Recombinant Zoster Vaccine in Japanese Adults Aged 65 Years and Older
por: Shiragami, Makoto, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_1id9931eht5nghvm4pilg7jvaa